Literature DB >> 7578401

A phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung.

R G Crystal1, A Jaffe, S Brody, A Mastrangeli, N G McElvaney, M Rosenfeld, C S Chu, C Danel, J Hay, T Eissa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7578401     DOI： 10.1089/hum.1995.6.5-643

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


× No keyword cloud information.
  13 in total

Review 1.  Prospects for gene therapy in cystic fibrosis.

Authors:  A Jaffé; A Bush; D M Geddes; E W Alton
Journal:  Arch Dis Child       Date:  1999-03       Impact factor: 3.791

Review 2.  Cell and gene therapy for genetic diseases: inherited disorders affecting the lung and those mimicking sudden infant death syndrome.

Authors:  Allison M Keeler; Terence R Flotte
Journal:  Hum Gene Ther       Date:  2012-06       Impact factor: 5.695

3.  Adenovirus type 37 uses sialic acid as a cellular receptor.

Authors:  N Arnberg; K Edlund; A H Kidd; G Wadell
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 4.  Chemoprotection of normal tissues by transfer of drug resistance genes.

Authors:  J A Rafferty; I Hickson; N Chinnasamy; L S Lashford; G P Margison; T M Dexter; L J Fairbairn
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 5.  Gene therapy for cystic fibrosis: challenges and future directions.

Authors:  J M Wilson
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

6.  Viral Vectors, Animal Models, and Cellular Targets for Gene Therapy of Cystic Fibrosis Lung Disease.

Authors:  Yinghua Tang; Ziying Yan; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2020-04-15       Impact factor: 5.695

7.  Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase.

Authors:  A Amalfitano; A J McVie-Wylie; H Hu; T L Dawson; N Raben; P Plotz; Y T Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 8.  Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.

Authors:  T M Clay; M C Custer; P J Spiess; M I Nishimura
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

9.  Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer.

Authors:  R J Pickles; D McCarty; H Matsui; P J Hart; S H Randell; R C Boucher
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

Review 10.  Advances in gene therapy for cystic fibrosis lung disease.

Authors:  Ziying Yan; Paul B McCray; John F Engelhardt
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 5.121
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.